Premium
Do shrimp‐allergic individuals tolerate shrimp‐derived glucosamine?
Author(s) -
Villacis J.,
Rice T. R.,
Bucci L. R.,
ElDahr J. M.,
Wild L.,
DeMerell D.,
Soteres D.,
Lehrer S. B.
Publication year - 2006
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.2006.02590.x
Subject(s) - shrimp , glucosamine , medicine , allergy , allergen , immunology , biology , fishery , biochemistry
Summary Background There is concern that shrimp‐allergic individuals may react to glucosamine‐containing products as shrimp shells are a major source of glucosamine used for human consumption. Objective The purpose of this study was to determine whether shrimp‐allergic individuals can tolerate therapeutic doses of glucosamine. Methods Subjects with a history of shrimp allergy were recruited and tested for both shrimp reactivity via a prick skin test and shrimp‐specific IgE by an ImmunoCAP assay. Fifteen subjects with positive skin tests to shrimp and an ImmunoCAP class level of two or greater were selected for a double‐blind placebo‐controlled food challenge (DBPCFC) using glucosamine‐chondroitin tablets containing 1500 mg of synthetically produced (control) or shrimp‐derived glucosamine. Immediate reactions, including changes in peak flow and blood pressure, and delayed reactions (up to 24 h post‐challenge) via questionnaire were noted and assessed. Results All subjects tolerated 1500 mg of both shrimp‐derived or synthetic glucosamine without incident of an immediate hypersensitivity response. Peak flows and blood pressures remained constant, and no subject had symptoms of a delayed reaction 24 h later. Conclusion This study demonstrates that glucosamine supplements from specific manufacturers do not contain clinically relevant levels of shrimp allergen and therefore appear to pose no threat to shrimp‐allergic individuals.